Therapy News and Research

RSS

Dr. Reddy’s initiates DRL-17822 Phase II study in type II dyslipidemia

Dr. Reddy's Laboratories announced the initiation of dosing with DRL-17822 in patients with diagnosis of type II dyslipidemia. DRL-17822 is a selective, orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), for the treatment and/or prevention of dyslipidemia, atherosclerosis and associated cardiovascular disease.

2 Sep 2011

New implantable micro oxygen generator improves effectiveness of anticancer tharapy

Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.

2 Sep 2011

Valproic acid may increase survival for brain tumor patients

New research suggests brain tumor patients who take the seizure drug valproic acid on top of standard treatment may live longer than people who take other kinds of epilepsy medications to control seizures.

2 Sep 2011

Two ALS-associated genes work in tandem to support long-term survival of motor neurons

Although several genes have been linked to amyotrophic lateral sclerosis (ALS), it is still unknown how they cause this progressive neurodegenerative disease. In a new study, Columbia University Medical Center (CUMC) researchers have demonstrated that two ALS-associated genes work in tandem to support the long-term survival of motor neurons.

2 Sep 2011

Dendritic cells play central role in regulation of acetaminophen's toxicity

NYU School of Medicine researchers have discovered that dendritic cells in the liver have a protective role against the toxicity of acetaminophen, the widely used over-the-counter pain reliever and fever reducer for adults and children.

2 Sep 2011

CRI announces winners of 2011 Coley Award for distinguished research in tumor immunology

The Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization established in 1953 to advance the science of tumor immunology and drive the discovery of new cancer immunotherapies, announced today the winners of the 2011 William B. Coley Award for Distinguished Research in Tumor Immunology.

2 Sep 2011

Engineered virus shows promise in cancer therapy via bloodstream

Scientists have engineered a virus that when injected into the blood, can selectively target cancer cells throughout the body. The virus attacked only tumours, leaving the healthy tissue alone, in a small trial on 23 patients, according to the journal Nature.

2 Sep 2011

LCA applauds FDA approval of Xalkori for ALK positive non-small cell lung cancer

Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive. The drug was approved based on data from two clinical trials, both of which showed a significant increase in overall survival.

2 Sep 2011

Further acne treatment studies necessary: Experts

Researchers writing in the journal The Lancet suggest further research that is urgently needed for effective non-antibiotic treatments for acne, because of concerns regarding long-term antibiotic use and its contribution to bacterial resistance. Pharmacies are well stocked with a wide range of acne medications. However, evidence regarding their efficacy and which treatments work best for whom are limited, the authors added.

31 Aug 2011

Prostate cancer linked to pesticides: Study

Researchers at the University of Southern California (USC) have found an increased prevalence of prostate cancer among older men exposed to certain pesticides in Central Valley neighborhoods.

31 Aug 2011

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

It’s said a lot can happen in seven days. In seven years, a lot has happened in the understanding of acromegaly, a debilitating condition that causes a patient to have too much growth hormone. It’s seven years since the American Association of Clinical Endocrinologists last produced guidelines for the diagnosis and treatment of acromegaly. Their 2004 guidelines were just 13 pages long. Their latest, the 2011 guidelines, have grown – to 44 pages.

31 Aug 2011

First Edition: August 31, 2011

Today's headlines include details about the GOP tax expert who has been named to help run the deficit-reduction "super committee" as well as the health policy ideas Republican governors are offering in the context of the nation's fiscal fix.

31 Aug 2011

Medivir reports net sales of SEK 444.6 m for 1 January - 30 June 2011

Medivir: Interim period (January 2011 - June 2011). Net sales were SEK 444.6 (35.7) m.

31 Aug 2011

Research shows numerous health benefits of Modified Citrus Pectin

New research published in the journal BMC Complementary and Alternative Medicine shows Modified Citrus Pectin (MCP) packs a powerful immune punch.

31 Aug 2011

Symptom-based viral load testing detects HIV in MSM

Testing for HIV when flu-like symptoms develop may offer a cost-effective alternative for early detection of HIV infection in men who have sex with men (MSM), reports a study in the journal AIDS.

31 Aug 2011

Patients with sarcopenia more likely to have worse outcomes from melanoma

It's not how old but how frail patients are that can predict how well they will fare after a melanoma diagnosis. In fact, young patients in poor health may have worse outcomes than older patients in good shape.

31 Aug 2011

NSU's iPad program treats spinal cord injuries

A little iPad can go a long way. At Nova Southeastern University (NSU), the tiny, flat screen, touch pad is being used by the Occupational Therapy Department researchers to treat disabled patients who suffer from spinal cord injuries and other disabilities.

31 Aug 2011

Yoga as therapy in neuropsychiatric disorders

Yoga is commonly seen as a practice beneficial to body and mind. Increasingly, yoga is being taken a step further and applied as a form of complementary and alternative medicine in treating psychiatric disorders.

31 Aug 2011

Positive results from Bionovo's Menerba tolerability trial on menopausal hot flashes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced the positive results from the completion of their tolerability trial of Menerba (MF101) for menopausal hot flashes.

31 Aug 2011

Viewpoints: States' anti-abortion laws; unproven cancer therapy; paying for retirees' health benefits

Since last year, 13 states, including Kansas, have enacted laws banning insurance coverage of abortion in the health insurance exchanges created by the federal health care reform law. Some states have gone even further, aggressively restricting abortion coverage even in private insurance plans sold outside the exchanges. ... These cases, some of which are being appealed, are testing whether the antiabortion movement will get its way. It shouldn't.

31 Aug 2011